
Australia is one of the most geographically isolated countries in the world, which has resulted in the evolution of a distinct microflora resulting from this unique biodiversity. Actinobacteria are historically one of the most prolific sources of microbial natural products, and the Actinobacteria isolated from Australian soil have led to the discovery of several novel bioactive compounds in recent years. The Australian ecosystem contains diverse rare and novel actinomycetes, including novel Streptomycetes , and most remain untapped for new compound discovery. This review summarizes novel natural products and analogs of previously reported compounds which isolated from Actinobacteria collected from isolates gathered across the Australian continent in recent 5 years and discusses the biological activities uncovered. These compounds should be further probed to gain insights about their mode of activity, thus identifying potential leads for next‐generation candidates for anticancer agents, antibiotics, and anthelmintics.
Specific tumor biomarkers visualization by molecular magnetic resonance imaging (MRI) enables early cancer detection before morphologic changes appear. Herein, we designed a peptide targeting moiety (GEVMPTLDMALFDWTDYEDLKP) for the extracellular emerging biomarker Netrin‐1, which was first conjugated to a DOTA‐like chelator ( G ). 111 In‐ G highlighted small tumors in an orthotopic murine model of triple‐negative metastatic breast cancer (4T1) by single‐photon emission computerized tomography (SPECT). Nevertheless, 111 In‐ G had very high kidney uptake which prevailed 24 h post‐injection. To prevent potential toxicity for MRI Gd‐analog, injected in higher dose due to MRI’s low sensibility, we developed a novel targeted liposome formulation, ( 111 In)‐Gd‐L G . Liposomes contain PEGylated phospholipids functionalized with the new targeting peptide and amphiphilic Gd 3+ / 111 In 3+ chelates enabling multimodal MRI and/or SPECT detection. The formulation was optimized and characterized by dynamic light scattering and 1 H relaxometry. In the same 4T1 murine model, ex vivo biodistribution evidenced significantly reduced liposomes kidney uptake (4 vs. 137%ID/g for 111 In‐Gd‐L G versus 111 In‐ G , 4 h post injection), retaining tumor detection capabilities. Successful in vivo MRI visualization of small tumors (<50 mm 3 ) at 0.03 mmol/kg Gd dose, provided similar signal enhancement as the clinical agent Dotarem at a 7‐fold higher dose. Data reinforce Netrin‐1’s potential targeting as cancer‐specific imaging approaches.
Recent studies on thiazolide antivirals have identified compounds RM5038 and RM5021 as potent inhibitors of hepatitis B virus (HBV), hepatitis C virus (HCV), and influenza A, although their development has been limited by poor aqueous solubility and rapid metabolic clearance. In this work, a series of novel halogen‐substituted and 4′‐alkylsulfone thiazolide analogs were synthesized using updated convergent synthetic approaches and flexible protecting group strategies. DMPK evaluation demonstrated that 3‐X halogen substitution significantly improved aqueous solubility in parallel to enhancing metabolic stability. Within the chlorothiazolide series, compounds 10g and 10l displayed much improved metabolic stability profiles, excellent aqueous solubility representing a 10‐fold improvement over the parent drug, together with low single‐digit micromolar antiviral (influenza A) activity and acceptable in vitro safety indices. Evaluation of the 4′‐alkylsulfone thiazolides also revealed improved in vitro DMPK profiles while retaining micromolar antiviral potency. SAR analysis indicated that short alkyl sulfone substituents containing two to three carbons are optimal for antiviral activity, while branched alkyl groups may provide additional metabolic advantages. In summary, compounds 10g, 10l, and 15d represent promising early leads for progression to in vivo profiling and additional preclinical evaluation.
AL amyloidosis is a protein‐misfolding disorder caused by deposition of immunoglobulin light‐chain variable domains. Lambda chains account for ≈80% of cases and kappa for ≈20%. We performed high‐resolution mass spectrometry and bioinformatics on biopsies from 25 patients (15 kappa‐type, 9 lambda‐type, 1 mixed). We identified 42 unique IGKV and 11 IGLV sequences; IGKV3‐20, IGKV1‐39/1D‐39, and IGLV1‐40 were most frequent. Because immunoglobulin variable‐domain sequences are highly homologous, some identifications are reported at the family or subfamily level. Amino acid substitutions clustered in FR1 and FR3. Using FoldAmyloid, PASTA, AGGRESCAN, and Waltz, we evaluated the amyloidogenicity of native and mutant proteins. Several mutations altered aggregation: I70/54V in IGKV1 ‐ 27 abolished Waltz‐predicted amyloidogenic stretch, while T42/22L in IGKV1‐5 created a new AGGRESCAN hotspot. Notably, eight identified sequences (IGKV3‐7, IGKV1/OR2‐108, IGKV6D‐21, IGKV6‐21, IGKV1D‐42, IGKV6D‐41, IGKV3/OR2‐268, IGLV1‐50) are absent from the AL‐Base database, suggesting that rare germline variants may carry a higher amyloidogenic risk. Our study underscores the value of combining proteomics and computational analysis for precise amyloid typing and for identifying mutations that may influence disease progression.
Photodynamic therapy (PDT) is significantly constrained in hypoxic tumor microenvironments (TMEs) because conventional Type II photosensitization depends strongly on molecular oxygen for efficient singlet oxygen generation. This limitation has stimulated increasing interest in Type I photosensitizers, which initiate photochemical reactions through electron or hydrogen transfer and can retain reactive oxygen species (ROS)‐generating activity under reduced oxygen availability. In some Type I PDT systems, additional oxygen‐regulating processes can further alleviate local hypoxia, thereby sustaining O 2 − ‐dependent downstream ROS generation while contributing to the modulation of the TME. These properties also support combination strategies with photothermal therapy, immunotherapy, or chemotherapy to enhance therapeutic outcomes. This review systematically examines Type I photosensitizers within a framework linking molecular design, photophysical and photochemical properties, mechanistic pathways, and biomedical applications. Their classification, structure–property relationships, and mechanisms of action are critically examined, with particular emphasis on recent advances in hypoxia‐tolerant PDT, multimodal combination therapy, and imaging‐guided theranostics. Finally, the remaining challenges and future directions are discussed with the aim of facilitating the translation of Type I photosensitizers from fundamental research toward clinical cancer theranostics.